Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RGX 181

Next Previous
Search
Drug Profile

RGX 181

Alternative Names: AAV9.hCLN2; RGX-181

Latest Information Update: 13 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REGENXBIO
  • Class Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Tripeptidyl-peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuronal ceroid lipofuscinosis

Most Recent Events

  • 13 Nov 2023 RGX 181 is available for licensing as of 09 Nov 2023. https://www.regenxbio.com/therapeutic-programs/
  • 08 Sep 2023 Phase-I clinical trials in Neuronal ceroid lipofuscinosis (In children) in Europe, USA (Intracisternal) before September 2023
  • 30 Aug 2023 Efficacy and adverse events data from a single-patient, investigator-initiated trial in Neuronal ceroid lipofuscinosis type 2 (CLN2) disease released by regenxbio

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top